Revenue growth remains strong and losses are narrowing, but the EPS miss relative to consensus may cause short-term pressure. The key catalyst is TEBE-AM Phase 3 data expected by end of 2026, a positive readout could significantly expand KIMMTRAK's addressable market into cutaneous melanoma. Monitor upcoming pipeline data presentations in H2 2026.
Drug in focus
IMCR drug pipeline →KIMMTRAK
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized (since January 2022). Label expansion into cutaneous melanoma depends on Phase 3 TEBE-AM data expected by end of 2026; if positive, an sBLA submission would follow, with potential approval in 2027-2028.
- Next catalyst
- None dated
What to watchThe key near-term catalyst is the Phase 3 TEBE-AM topline readout for KIMMTRAK in cutaneous melanoma, expected by end of 2026 (~4 months away). A positive result could double the addressable market; a negative readout would be a major setback. With ~16.4% of shares short and ~18.8 days to cover, a positive readout could trigger significant short-covering upside. Watch for enrollment completion announcements and any data updates at medical meetings in H2 2026.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $34.50entry
- T+1 · 3mo ago −1.45%α −2.06% · $34.00
- T+5 · 3mo ago −0.87%α −2.08% · $34.20
- T+20 · 3mo ago +8.90%α +8.30% · $37.57
- T+60 · 18d ago −11.62%α −9.95% · $30.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immunocore reported Q2 2026 KIMMTRAK revenue of $115.9M (+18% YoY), beating consensus of $110.4M, but posted a small net loss of $0.8M ($-0.02 EPS) vs consensus expectations of $0.02 EPS. The EPS miss was driven by higher R&D spend on three Phase 3 trials. Cash position remains strong at $880M. Enrollment in the pivotal TEBE-AM trial for cutaneous melanoma is nearing completion with data possible by year-end.
Key Financial Metrics
Key Facts
- Q2 2026 KIMMTRAK net revenue $115.9M, up 18% YoY from $98.0M
- Net loss of $0.8M ($-0.02 EPS) vs net loss of $10.3M ($-0.20 EPS) in Q2 2025
- Revenue beat consensus of $110.4M; EPS missed consensus of $0.02
- Cash, cash equivalents and marketable securities $880.2M as of June 30, 2026
- Enrollment in Phase 3 TEBE-AM trial nearing target of 540 patients; topline data possible end of 2026
- Phase 3 PRISM-MEL-301 (brenetafusp) and ATOM (adjuvant uveal melanoma) trials ongoing
Financial Impact
Revenue grew 18% YoY to $115.9M; net loss narrowed to $0.8M from $10.3M; EPS miss of -$0.04 vs consensus
Risk Factors
- KIMMTRAK is the sole revenue source; any sales disruption or competitive threat would materially impact financials
- Clinical trial risks for TEBE-AM, PRISM-MEL-301, and ATOM trials
- Expected $120M in sales-related rebate payments in H2 2026 could pressure cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001671927-26-000020 |
| Document: imcr-20260806.htm | 0001671927-26-000020 |
| Document: 0001671927-26-000020-index-headers.html | 0001671927-26-000020 |
| Document: 0001671927-26-000020-index.html | 0001671927-26-000020 |
| Document: 0001671927-26-000020.txt | 0001671927-26-000020 |
| 8-K Data (Synthetic) | 0001671927-26-000020 |
Track record
14 reports on IMCR
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +28.39% at T+60 after the May 31, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
- Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
- Aug 6, 202614w ago 8-K Mixed 5/10 Viewing Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
- May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers